Please provide your email address to receive an email when new articles are posted on . Patients were given a single dose of 1,000mg of IV iron or placebo. Researchers found no mean between-group ...

Randomized controlled trial finds no significant difference between high- and low-dose intravenous iron with respect to mortality, non-fatal cardiovascular outcomes, and infection. SAN ...

SAN DIEGO—Non-dialysis chronic kidney disease (CKD) patients receiving intravenous (IV) iron therapy may have increased risks for infection, according to a poster presentation at the American Society ...

Buenos Aires, Argentina - A small placebo-controlled study, adding to the scant published data on the use of IV-iron therapy without concomitant erythropoiesis-stimulating agents in patients with ...

This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?" Management ...

A recent study published in the journal of BMC Nephrology revealed that no significant relationship between high-sensitivity ...

The Germany iron deficiency anemia therapy market size is calculated at USD 431.53 million in 2025 and is expected to reach ...

None of the IV iron products were found to be associated with an increased risk of adverse or serious adverse events compared with oral iron The safety profiles of various intravenous (IV) iron ...

A global study led by researchers at The University of Western Australia has addressed the rising use of intravenous iron therapy in anemic patients during major surgery and found there is little ...

Injectafer, made by Daiichi Sankyo, is a ferric carboxymaltose injection treatment for iron deficiency in adult patients with heart failure to improve exercise capacity, according to a June 5 company ...